文献速递糖尿病

SGLT2抑制剂与非奈利酮在2型糖尿病合并CKD患者中的心肾疗效与安全性比较

Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-13

结果显示两类药物均降低肾功能进展和心衰住院风险,间接比较中SGLT2抑制剂在肾功能进展和心衰住院方面更优,但所有类别间比较的证据确定性为低或极低。

要点

  • SGLT2抑制剂与非奈利酮均能降低肾功能进展和心衰住院风险
  • 间接比较中SGLT2抑制剂在肾功能进展方面优势在敏感性分析后仍持续
  • 所有类别间比较的确定性为低或极低,不应据此对药物排序

核心结论

  • SGLT2抑制剂与非奈利酮均提供心肾保护,且似乎是互补而非可互换的

研究设计与样本

  • 检索MEDLINE、Embase、CENTRAL和试验注册库自建库至2026年8月的安慰剂对照结局试验
  • 采用频率学随机效应网络荟萃分析,通过安慰剂间接推导类别间对比
  • 偏倚风险采用RoB 2,证据确定性采用CINeMA评价

主要发现

  • 与安慰剂相比,两类药物均降低肾功能进展,SGLT2抑制剂HR 0.64(95%CI 0.56-0.73),非奈利酮HR 0.84(95%CI 0.77-0.92)
  • 与安慰剂相比,两类药物均降低心衰住院,SGLT2抑制剂HR 0.61(95%CI 0.53-0.69),非奈利酮HR 0.78(95%CI 0.66-0.92)
  • 间接比较中SGLT2抑制剂在肾功能进展更优HR 0.76(95%CI 0.64-0.90),心衰住院更优HR 0.77(95%CI 0.63-0.95)
  • 动脉粥样硬化血栓事件和死亡率无显著差异
  • 非奈利酮增加高钾血症但未增加急性肾损伤

关键数值与推荐

  • 间接比较SGLT2抑制剂对肾功能进展HR 0.76,95%CI 0.64-0.90
  • 间接比较SGLT2抑制剂对心衰住院HR 0.77,95%CI 0.63-0.95
  • 排除高偏倚风险数据集、限制于专门CKD试验并应用统一终点后,肾脏对比仍显著
  • 在专门CKD试验中心衰对比不持续

临床怎么用

  • 两类药物均可在2型糖尿病合并CKD患者中用于心肾保护
  • 间接比较的差异属假设生成性质,不应据此对药物排序

局限性

  • 星形网络无闭合环,无法验证传递性假设
  • 所有类别间比较的证据确定性为低或极低
  • 安全性领域在类别间报告不可比

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims No randomized trial has compared SGLT2 inhibitors with finerenone in chronic kidney disease (CKD) with Type 2 diabetes. We estimated their comparative cardiorenal efficacy and safety. Materials and Methods MEDLINE, Embase, CENTRAL and trial registries were searched from inception to August 2026 for placebo-controlled outcome trials. Hazard ratios (HRs) were pooled in a frequentist random-effects network meta-analysis, and the between-class contrast was derived indirectly through placebo. Risk of bias followed RoB 2 and certainty followed CINeMA. Results Ten trial datasets formed a star network without closed loops. Versus placebo, both classes reduced kidney function progression (SGLT2 inhibitors HR: 0.64, 95% CI: 0.56–0.73; finerenone 0.84, 0.77–0.92) and heart-failure hospitalization (0.61, 0.53–0.69; 0.78, 0.66–0.92). Indirectly, SGLT2 inhibitors were favoured for kidney function progression (0.76, 0.64–0.90) and heart-failure hospitalization (0.77, 0.63–0.95), with no significant difference for atherothrombotic events or mortality. The kidney contrast remained significant after excluding high-risk-of-bias datasets, restricting to dedicated CKD trials and applying a uniform endpoint; the heart-failure contrast did not persist in dedicated CKD trials. Finerenone increased hyperkalemia without increasing acute kidney injury. Certainty was low or very low for every between-class comparison. Conclusions SGLT2 inhibitors and finerenone both provide cardiorenal protection and appear complementary rather than interchangeable. Indirect differences favouring SGLT2 inhibitors derive from a loop-free network with unverifiable transitivity and low certainty; they are hypothesis-generating and should not be used to rank the agents. Safety domains are not reported comparably across classes. Trial Registration CRD420261439899

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。